4-(Pyridin-4-yl)-N-(3-(trifluoromethoxy)benzyl)benzamide

ID: ALA4475535

PubChem CID: 155538076

Max Phase: Preclinical

Molecular Formula: C20H15F3N2O2

Molecular Weight: 372.35

Molecule Type: Unknown

This compound is available for customization.

Associated Items:

Names and Identifiers

Canonical SMILES:  O=C(NCc1cccc(OC(F)(F)F)c1)c1ccc(-c2ccncc2)cc1

Standard InChI:  InChI=1S/C20H15F3N2O2/c21-20(22,23)27-18-3-1-2-14(12-18)13-25-19(26)17-6-4-15(5-7-17)16-8-10-24-11-9-16/h1-12H,13H2,(H,25,26)

Standard InChI Key:  BGSKZKNLGRQZGZ-UHFFFAOYSA-N

Molfile:  

 
     RDKit          2D

 27 29  0  0  0  0  0  0  0  0999 V2000
   23.0657  -10.2190    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   23.0645  -11.0426    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   23.7767  -11.4516    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   24.4905  -11.0422    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   24.4876  -10.2154    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   23.7749   -9.8060    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   25.1949   -9.8013    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   25.9044  -10.2130    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   26.6143   -9.7983    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   26.6116   -8.9762    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   25.8933   -8.5704    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   25.1905   -8.9833    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   27.3214   -8.5640    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   28.0353   -8.9689    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   27.3172   -7.7427    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   28.7450   -8.5567    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   29.4589   -8.9617    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   29.4616   -9.7826    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   30.1746  -10.1916    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   30.8812   -9.7753    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   30.8744   -8.9497    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   30.1649   -8.5485    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   31.5827   -8.5350    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   32.2980   -8.9375    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   33.0063   -8.5228    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
   32.3051   -9.7588    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
   33.0054   -9.3482    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  2  0
  2  3  1  0
  3  4  2  0
  4  5  1  0
  5  6  2  0
  6  1  1  0
  7  8  2  0
  8  9  1  0
  9 10  2  0
 10 11  1  0
 11 12  2  0
 12  7  1  0
  5  7  1  0
 10 13  1  0
 13 14  1  0
 13 15  2  0
 14 16  1  0
 16 17  1  0
 17 18  2  0
 18 19  1  0
 19 20  2  0
 20 21  1  0
 21 22  2  0
 22 17  1  0
 21 23  1  0
 23 24  1  0
 24 25  1  0
 24 26  1  0
 24 27  1  0
M  END

Alternative Forms

  1. Parent:

    ALA4475535

    ---

Associated Targets(Human)

ROCK1 Tclin Rho-associated protein kinase 1 (4723 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
ROCK2 Tclin Rho-associated protein kinase 2 (6206 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: UnknownTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 372.35Molecular Weight (Monoisotopic): 372.1086AlogP: 4.58#Rotatable Bonds: 5
Polar Surface Area: 51.22Molecular Species: NEUTRALHBA: 3HBD: 1
#RO5 Violations: HBA (Lipinski): 4HBD (Lipinski): 1#RO5 Violations (Lipinski):
CX Acidic pKa: CX Basic pKa: 4.95CX LogP: 4.63CX LogD: 4.63
Aromatic Rings: 3Heavy Atoms: 27QED Weighted: 0.71Np Likeness Score: -1.29

References

1. Hobson AD, Judge RA, Aguirre AL, Brown BS, Cui Y, Ding P, Dominguez E, DiGiammarino E, Egan DA, Freiberg GM, Gopalakrishnan SM, Harris CM, Honore MP, Kage KL, Kapecki NJ, Ling C, Ma J, Mack H, Mamo M, Maurus S, McRae B, Moore NS, Mueller BK, Mueller R, Namovic MT, Patel K, Pratt SD, Putman CB, Queeney KL, Sarris KK, Schaffter LM, Stoll V, Vasudevan A, Wang L, Wang L, Wirthl W, Yach K..  (2018)  Identification of Selective Dual ROCK1 and ROCK2 Inhibitors Using Structure-Based Drug Design.,  61  (24): [PMID:30384606] [10.1021/acs.jmedchem.8b01098]

Source